Clinical Trial Detail

NCT ID NCT02936752
Title Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Entinostat + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.